Compare · ARGX vs IVVD
ARGX vs IVVD
Side-by-side comparison of argenx SE (ARGX) and Invivyd Inc. (IVVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IVVD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $61.09B, about 263.9x IVVD ($231.5M).
- Over the past year, ARGX is up 29.8% and IVVD is down 44.6% - ARGX leads by 74.5 points.
- IVVD has been more active in the news (13 items in the past 4 weeks vs 10 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- argenx SE
- Invivyd Inc.
- Price
- $984.13-0.03%
- $0.79+1.31%
- Market cap
- $61.09B
- $231.5M
- 1M return
- +12.34%
- +7.54%
- 1Y return
- +29.84%
- -44.64%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 10
- 13
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Completes Acquisition of Forte Biosciences, Inc.
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Latest IVVD
- Invivyd to Participate in Upcoming September Investor Conferences
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Sheffield Ian
- SEC Form 3 filed by new insider Sheffield Ian
- SEC Form 4 filed by Chief Executive Officer Elia Marc
- Invivyd Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
- Chief Financial Officer Duke William E. converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) (for withholding tax)
- Chief Human Resources Officer Green Julie converted options into 102,000 shares and sold $31,671 worth of shares (40,780 units at $0.78) as part of a pre-agreed trading plan, increasing direct ownership by 57% to 168,937 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Allen Robert D. Iii sold $29,296 worth of shares (37,722 units at $0.78) as part of a pre-agreed trading plan and converted options into 102,000 shares, increasing direct ownership by 56% to 178,765 units (SEC Form 4) to satisfy withholding tax